AstraZeneca's Legal Troubles Continue To Mount

Law360, New York (December 21, 2006, 12:00 AM EST) -- Days after the European Patent Office rejected a key substance-of-matter patent covering drug giant AstraZeneca’s blockbuster heartburn drug Nexium, antitrust challenges continue to mount over the drug in the United States.

Lawsuits continue to trickle in alleging that AstraZeneca has illegally controlled the market by shifting its support to Nexium from Prilosec as Prilosec lost patent protection.

Two suits were filed this week in the U.S. District Court for the District of Columbia. Louisiana Wholesale Drug Co. Inc., a wholesaler which reportedly covers 65% of independent...
To view the full article, register now.